semaglutide patent protection (Ozempic) Market: Navigating The Cliff And Strategic Implications The upcoming expiry of the

Wegovy is approved for weight loss (2.4 mg)

Discussion This is the first systematic review and meta-analysis focused exclusively on RCTs evaluating major cardiovascular events (MACE)

Patients with Renal impairment - Renal impairment does not impact the pharmacokinetics of semaglutide in a clinically relevant manner

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily prescribed for type 2 diabetes management and, more recently, for chronic weight management

Each month, patients increase their dosage with each injection, starting at 0.25mg then up to 0.5mg, 1mg, 1.7mg and finally maxing out at 2.4mg